Body Composition Analysis and Time to Emergence From Remimazolam

Samsung Medical Center

Status: Invitation-only

Conditions: Remimazolam; Body Composition

Treatments: Device: body composition analysis

Study type: Observational

Funder types: Other

Identifiers

NCT05512559

SMC 2022-06-074

Details and patient eligibility

About

Remimazolam is a novel general anesthetic drug. The time to emergence from remimazolam-based general anesthesia is variable among patients, but little is known about the risk factors for delayed emergence. We believe that information from body composition analysis may be helpful in understanding which patients are more likely to show delayed emergence from remimazolam.

Enrollment: 90 estimated patients

Sex: All

Ages: 19+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult ASA I-III patients undergoing cerebral aneurysm coil embolization under general anesthesia using remimazolam

Exclusion criteria

• Patients with preoperative mental change, hemodynamic instability, hemodialysis, heart failure, hypoalbuminemia, pregnancy

Trial design

90 participants in 1 patient group

remimazolam

Description:

general anesthesia induction with 6mg/kg/hr continuous infusion of remimazolam. general anesthesia maintenance with 1mg/kg/hr continuous infusion of remimazolam.

Treatment:

Device: body composition analysis